{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:56:18Z","timestamp":1790056578792,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>It may be impossible to perform cancer surgery with free margins in the presence of an unresectable structure. Local drug treatment after surgery has been proposed to increase the rate of tumor control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Multi-nanolayers (10-330\u2009nm) were generated by a low-pressure (375mTorr) inductively coupled plasma (13.56\u2009MHz) reactor for anticancer drug delivery by the deposition of polycaprolactone-polyethylene glycol multistack barrier on the collagen membrane (100\u2009\u03bcm thickness). Carboplatin (300\u2009\u03bcg\/cm\n                      <jats:sup>2<\/jats:sup>\n                      ) was used for the in vitro and in vivo investigations. Energy-dispersive X-ray spectroscopy (15\u2009keV), scanning electron microscopy and inductively coupled plasma mass spectrometry were used to detect the presence of carboplatin in the nanolayer, the tumor sample and the culture medium. Preclinical studies were performed on ovarian (OVCAR-3NIH) and colon (CT26) cancer cell lines as\n                      <jats:italic>xenografts (45\u2009days)<\/jats:italic>\n                      and\n                      <jats:italic>allografts<\/jats:italic>\n                      (23\u2009days) in Swiss-nude (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) and immunocompetent BALB\/cByJ mice (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The loading of carboplatin or other drugs between the nanofilm on the collagen membrane did not modify the mesh complex architecture or the drug properties. Drugs were detectable on the membrane for more than 2 weeks in the in vitro analysis and more than 10\u2009days in the in vivo analysis. Cytotoxic mesh decreased cell adherence (down 5.42-fold) and induced cancer cell destruction (up to 7.87-fold). Implantation of the mesh on the mouse tumor nodule modified the cell architecture and decreased the tumor size (50.26%) compared to the control by inducing cell apoptosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Plasma technology allows a mesh to be built with multi-nanolayer anticancer drug delivery on collagen membranes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-06989-w","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T08:02:58Z","timestamp":1592380978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Multi-nanolayer drug delivery using radiofrequency plasma technology"],"prefix":"10.1186","volume":"20","author":[{"given":"Iman","family":"Al Dybiat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alibi","family":"Baitukha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Pimpie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Kaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pocard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Arefi Khonsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"6989_CR1","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/nbt1003-1137","volume":"21","author":"L Mazzola","year":"2003","unstructured":"Mazzola L. Commercializing nanotechnology. Nat Biotechnol. 2003;21:1137\u201343. https:\/\/doi.org\/10.1038\/nbt1003-1137.","journal-title":"Nat Biotechnol"},{"key":"6989_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nbt1003-1144","volume":"21","author":"R Paull","year":"2003","unstructured":"Paull R, Wolfe J, H\u00e9bert P, Sinkula M. Investing in nanotechnology. Nat Biotechnol. 2003;21:1144\u20137. https:\/\/doi.org\/10.1038\/nbt1003-1144.","journal-title":"Nat Biotechnol"},{"key":"6989_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-3155-2-3","volume":"2","author":"O Salata","year":"2004","unstructured":"Salata O. Applications of nanoparticles in biology and medicine. J Nanobiotechnol. 2004;2:3. https:\/\/doi.org\/10.1186\/1477-3155-2-3.","journal-title":"J Nanobiotechnol"},{"key":"6989_CR4","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/ijc.22709","volume":"120","author":"Y Liu","year":"2007","unstructured":"Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120:2527\u201337. https:\/\/doi.org\/10.1002\/ijc.22709.","journal-title":"Int J Cancer"},{"key":"6989_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2174\/156652410792630634","volume":"10","author":"R Seigneuric","year":"2010","unstructured":"Seigneuric R, Markey L, Nuyten DSA, Dubernet C, Evelo CTA, Finot E, Garrido C. From nanotechnology to nanomedicine: applications to cancer research. Curr Mol Med. 2010;10:640\u201352.","journal-title":"Curr Mol Med"},{"key":"6989_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nbt872","volume":"21","author":"GM Whitesides","year":"2003","unstructured":"Whitesides GM. The \u201cright\u201d size in nanobiotechnology. Nat Biotechnol. 2003;21:1161\u20135. https:\/\/doi.org\/10.1038\/nbt872.","journal-title":"Nat Biotechnol"},{"key":"6989_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ijrobp.2016.04.001","volume":"96","author":"AC Talleur","year":"2016","unstructured":"Talleur AC, Navid F, Spunt SL, McCarville MB, Wu J, Mao S, Davidoff AM, Neel MD, Krasin MJ. Limited margin radiation therapy for children and young adults with Ewing sarcoma achieves high rates of local tumor control. Int J Radiat Oncol Biol Phys. 2016;96:119\u201326. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.04.001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"6989_CR8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1097\/SLA.0000000000000978","volume":"260","author":"MK Angele","year":"2014","unstructured":"Angele MK, Albertsmeier M, Prix NJ, Hohenberger P, Abdel-Rahman S, Dieterle N, Schmidt M, Mansmann U, Bruns CJ, Issels RD, Jauch K-W, Lindner LH. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study. Ann Surg. 2014;260:749\u201354; discussion 754-756. https:\/\/doi.org\/10.1097\/SLA.0000000000000978.","journal-title":"Ann Surg"},{"key":"6989_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1021\/la980572l","volume":"15","author":"N Nishiyama","year":"1999","unstructured":"Nishiyama N, Yokoyama M, Aoyagi T, Okano T, Sakurai Y, Kataoka K. Preparation and characterization of self-assembled polymer\u2212metal complex micelle from cis -dichlorodiammineplatinum (II) and poly (ethylene glycol)\u2212Poly( \u03b1 ,\u03b2-aspartic acid) block copolymer in an aqueous medium. Langmuir. 1999;15:377\u201383. https:\/\/doi.org\/10.1021\/la980572l.","journal-title":"Langmuir"},{"key":"6989_CR10","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/wnan.1390","volume":"8","author":"X Duan","year":"2016","unstructured":"Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016;8:776\u201391. https:\/\/doi.org\/10.1002\/wnan.1390.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"6989_CR11","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1073\/pnas.1011379108","volume":"108","author":"S Dhar","year":"2011","unstructured":"Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011;108:1850\u20135. https:\/\/doi.org\/10.1073\/pnas.1011379108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6989_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/nn9014032","volume":"4","author":"S Aryal","year":"2010","unstructured":"Aryal S, Hu C-MJ, Zhang L. Polymer-Cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano. 2010;4:251\u20138. https:\/\/doi.org\/10.1021\/nn9014032.","journal-title":"ACS Nano"},{"key":"6989_CR13","doi-asserted-by":"publisher","first-page":"5958","DOI":"10.1016\/j.biomaterials.2006.08.016","volume":"27","author":"H Ye","year":"2006","unstructured":"Ye H, Jin L, Hu R, Yi Z, Li J, Wu Y, Xi X, Wu Z. Poly (gamma, L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials. 2006;27:5958\u201365. https:\/\/doi.org\/10.1016\/j.biomaterials.2006.08.016.","journal-title":"Biomaterials."},{"key":"6989_CR14","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/smll.201100001","volume":"7","author":"F Zhao","year":"2011","unstructured":"Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small Weinh Bergstr Ger. 2011;7:1322\u201337. https:\/\/doi.org\/10.1002\/smll.201100001.","journal-title":"Small Weinh Bergstr Ger"},{"key":"6989_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3390\/cancers3010061","volume":"3","author":"N-V Cuong","year":"2010","unstructured":"Cuong N-V, Jiang J-L, Li Y-L, Chen J-R, Jwo S-C, Hsieh M-F. Doxorubicin-loaded PEG-PCL-PEG micelle using Xenograft model of nude mice: effect of multiple Administration of Micelle on the suppression of human breast Cancer. Cancers. 2010;3:61\u201378. https:\/\/doi.org\/10.3390\/cancers3010061.","journal-title":"Cancers."},{"key":"6989_CR16","first-page":"357","volume":"4","author":"H Yasuda","year":"1989","unstructured":"Yasuda H, Iriyama Y. Plasma polymerization. Compr Polym Sci Suppl University of Missouri-Rolla, Rolla, MO, USA. 1989;4:357\u201375.","journal-title":"Compr Polym Sci Suppl University of Missouri-Rolla, Rolla, MO, USA"},{"key":"6989_CR17","doi-asserted-by":"publisher","unstructured":"Bhatt S, Pulpytel J, Ceccone G, Lisboa P, Rossi F, Kumar V, Arefi-Khonsari F. Nanostructure protein repellant amphiphilic copolymer coatings with optimized surface energy by inductively excited low pressure plasma. 2011. https:\/\/doi.org\/10.1021\/la203256w.","DOI":"10.1021\/la203256w"},{"key":"6989_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1680\/sufi.14.00008","volume":"3","author":"S Bhatt","year":"2015","unstructured":"Bhatt S, Pulpytel J, Arefi-Khonsari F. Low and atmospheric plasma polymerisation of nanocoatings for bio-applications. Surf Innov. 2015;3:63\u201383. https:\/\/doi.org\/10.1680\/sufi.14.00008.","journal-title":"Surf Innov"},{"key":"6989_CR19","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1021\/acs.chemrev.5b00634","volume":"116","author":"F Khelifa","year":"2016","unstructured":"Khelifa F, Ershov S, Habibi Y, Snyders R, Dubois P. Free-radical-induced grafting from plasma polymer surfaces. Chem Rev. 2016;116:3975\u20134005. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00634.","journal-title":"Chem Rev"},{"key":"6989_CR20","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1016\/j.polymer.2013.06.054","volume":"54","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Pulpytel J, Mirshahi M, Arefi-Khonsari F. Plasma co-polymerized nano coatings - As a biodegradable solid carrier for tunable drug delivery applications. Polymer. 2013;54:4820\u20139..","journal-title":"Polymer"},{"key":"6989_CR21","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1039\/C2RA21211K","volume":"2","author":"S Bhatt","year":"2012","unstructured":"Bhatt S, Pulpytel J, Mirshahi M, Arefi-Khonsari F. Nano thick poly(\u03b5-caprolactone)-poly (ethylene glycol) coatings developed by catalyst-free plasma assisted copolymerization process for biomedical applications. RSC Adv. 2012;2:9114\u201323. https:\/\/doi.org\/10.1039\/C2RA21211K.","journal-title":"RSC Adv"},{"key":"6989_CR22","doi-asserted-by":"publisher","first-page":"58121","DOI":"10.18632\/oncotarget.10932","volume":"7","author":"S Bhatt","year":"2016","unstructured":"Bhatt S, Valamanesh F, Pulpytel J, Lo Dico R, Baiyukha A, Al-Dybiat I, Pocard M, Arefi-Khonsari F, Mirshahi M. Radio-frequency plasma polymerized biodegradable carrier for in vivo release of cis-platinum. Oncotarget. 2016;7:58121\u201332. https:\/\/doi.org\/10.18632\/oncotarget.10932.","journal-title":"Oncotarget."},{"key":"6989_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2169-0022.1000499","volume":"7","author":"A Baitukha","year":"2018","unstructured":"Baitukha A, Al-Dybiat I, Valinataj-Omran A, Pulpytel J, Pocard M, Mirsha\u2019shi M, Arefi-Khonsari F. Low pressure plasma processing of collagen membranes for anti-Cancer drug delivery. J Mater Sci Eng. 2018;7:1\u20136. https:\/\/doi.org\/10.4172\/2169-0022.1000499.","journal-title":"J Mater Sci Eng"},{"key":"6989_CR24","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1002\/bip.22486","volume":"101","author":"S Chattopadhyay","year":"2014","unstructured":"Chattopadhyay S, Raines RT. Review collagen-based biomaterials for wound healing. Biopolymers. 2014;101:821\u201333. https:\/\/doi.org\/10.1002\/bip.22486.","journal-title":"Biopolymers."},{"key":"6989_CR25","unstructured":"Biom\u2019Up Advanced Biomaterials. Biom'Up S.A. 5. 510(k) Summary, CovaTMMAX Resorbable Collagen Membrane for Guided Tissue and Bone Regeneration, 8, Allee Irene Joliot-Curie 69800, Saint-Priest AUG 26, France (2011). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf10\/K103087.pdf."},{"key":"6989_CR26","unstructured":"The width of resection margins influences local recurrence in soft tissue sarcoma patients - European Journal of Surgical Oncology, (n.d.). https:\/\/www.ejso.com\/article\/S0748-7983(16)30040-3\/fulltext (Accessed 10 Dec 2018)."},{"key":"6989_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jso.25162","volume":"118","author":"JB Shewale","year":"2018","unstructured":"Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B. Predictors of survival after resection of primary sarcomas of the chest wall-a large, single-institution series. J Surg Oncol. 2018;118:518\u201324. https:\/\/doi.org\/10.1002\/jso.25162.","journal-title":"J Surg Oncol"},{"key":"6989_CR28","doi-asserted-by":"publisher","unstructured":"Zhou J, Atsina K-B, Himes BT, Strohbehn GW, Saltzman WM. Novel delivery strategies for glioblastoma. Cancer J Sudbury Mass. 2012;18. https:\/\/doi.org\/10.1097\/PPO.0b013e318244d8ae.","DOI":"10.1097\/PPO.0b013e318244d8ae"},{"key":"6989_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2016.09.034","volume":"243","author":"C Bastiancich","year":"2016","unstructured":"Bastiancich C, Danhier P, Pr\u00e9at V, Danhier F. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma. J Control Release. 2016;243:29\u201342. https:\/\/doi.org\/10.1016\/j.jconrel.2016.09.034.","journal-title":"J Control Release"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06989-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06989-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T19:13:19Z","timestamp":1623870799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06989-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6989"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06989-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21609\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of UPMC, France (APAFiS Number 3790). All experimental protocols were performed in accordance with the European Convention for the protection of vertebrate animals used for experimental and other scientific purposes (Council of Europe, 1986, ETS No. 123).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"565"}}